US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
CO4960662A1
(es)
*
|
1997-08-28 |
2000-09-25 |
Novartis Ag |
Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
|
EP1126841B1
(en)
*
|
1998-11-02 |
2004-12-15 |
Merck & Co., Inc. |
Combinations of a 5ht1b/1d agonist and a selective cox-2 inhibitor for the treatment of migraine
|
US20040053900A1
(en)
*
|
1998-12-23 |
2004-03-18 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
GB9922830D0
(en)
*
|
1999-09-27 |
1999-11-24 |
Novartis Ag |
Processes
|
AR030630A1
(es)
*
|
2000-09-11 |
2003-08-27 |
Novartis Ag |
Composiciones farmaceuticas
|
WO2002040018A1
(en)
*
|
2000-11-14 |
2002-05-23 |
Alcon, Inc. |
Treatment of glaucoma and ocular hypertension
|
US7656959B2
(en)
|
2001-04-13 |
2010-02-02 |
Agere Systems Inc. |
Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
|
US20050264906A1
(en)
*
|
2004-05-25 |
2005-12-01 |
Haratsch Erich F |
Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US20030114527A1
(en)
*
|
2001-08-31 |
2003-06-19 |
Karnachi Anees Abdulquadar |
Pharmaceutical composition
|
BR0212435A
(pt)
|
2001-09-10 |
2004-08-17 |
Sugen Inc |
Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
|
US7504231B2
(en)
*
|
2001-09-13 |
2009-03-17 |
The Board Of Regents Of The University Of Oklahoma |
Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
|
US7288246B2
(en)
*
|
2001-09-13 |
2007-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Method of alleviating chronic pain via peripheral glutaminase regulation
|
GB0124459D0
(en)
*
|
2001-10-11 |
2001-12-05 |
Novartis Ag |
Organic compounds
|
WO2003035047A2
(en)
*
|
2001-10-25 |
2003-05-01 |
Novartis Ag |
Combinations comprising a selective cyclooxygenase-2 inhibitor
|
CA2461373A1
(en)
*
|
2001-11-06 |
2003-05-15 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
GB0201520D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Pharmaceutical uses
|
KR20040089654A
(ko)
*
|
2002-03-07 |
2004-10-21 |
노파르티스 아게 |
약제학적 조성물
|
GB0209257D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
US7220749B2
(en)
*
|
2002-06-11 |
2007-05-22 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
ITMI20021391A1
(it)
|
2002-06-25 |
2003-12-29 |
Nicox Sa |
Nitroderivati di inibitori della cicloossigenasi-2
|
CA2492989C
(en)
|
2002-07-23 |
2012-11-20 |
Novartis Ag |
Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
WO2004028448A2
(en)
*
|
2002-09-13 |
2004-04-08 |
Miller Kenneth E |
Method of alleviating pain via inhibition of neurotransmitter synthesis
|
GB0224198D0
(en)
*
|
2002-10-17 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
US7632866B2
(en)
|
2002-10-21 |
2009-12-15 |
Ramot At Tel Aviv University |
Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
AR042206A1
(es)
*
|
2002-11-26 |
2005-06-15 |
Novartis Ag |
Acidos fenilaceticos y derivados
|
US20040204411A1
(en)
*
|
2002-12-17 |
2004-10-14 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
CN1726030A
(zh)
*
|
2002-12-18 |
2006-01-25 |
诺瓦提斯公司 |
缬沙坦与cox-2抑制剂的组合
|
US7157577B2
(en)
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
TWI327913B
(en)
*
|
2003-03-12 |
2010-08-01 |
Novartis Ag |
Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
WO2004093895A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093814A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
|
WO2004093816A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
|
WO2004093813A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
ATE342722T1
(de)
|
2003-05-07 |
2006-11-15 |
Osteologix As |
Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
US20050026919A1
(en)
*
|
2003-05-14 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
|
US7220422B2
(en)
*
|
2003-05-20 |
2007-05-22 |
Allergan, Inc. |
Methods and compositions for treating eye disorders
|
US20060160776A1
(en)
*
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
US20050101597A1
(en)
*
|
2003-07-10 |
2005-05-12 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
US20050075341A1
(en)
*
|
2003-07-17 |
2005-04-07 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
SA04250253B1
(ar)
|
2003-08-21 |
2009-11-10 |
استرازينيكا ايه بي |
احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
|
WO2005018563A2
(en)
*
|
2003-08-22 |
2005-03-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
US20050113409A1
(en)
*
|
2003-09-03 |
2005-05-26 |
Pharmacia Corporation |
Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
|
JP2007511468A
(ja)
*
|
2003-10-03 |
2007-05-10 |
ファルマシア コーポレイション |
虚血仲介中枢神経系障害又は損傷の治療のための低体温状態下で投与されるシクロオキシゲナーゼ−2選択的阻害剤の組成物
|
CA2541265A1
(en)
*
|
2003-10-08 |
2005-04-28 |
Novartis Ag |
Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
|
WO2005046615A2
(en)
*
|
2003-11-12 |
2005-05-26 |
Pharmacia & Upjohn Company Llc |
Compositions for treatment of central nervous system mediated disorders
|
NZ549010A
(en)
|
2004-01-07 |
2010-07-30 |
Seikagaku Kogyo Co Ltd |
Hyaluronic acid derivative and drug containing the same
|
WO2005089718A2
(en)
|
2004-03-23 |
2005-09-29 |
Novartis Ag |
Pharmaceutical compositions
|
TW200603792A
(en)
*
|
2004-04-23 |
2006-02-01 |
Pharmacia & Upjohn Co Llc |
Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
|
US7380199B2
(en)
*
|
2004-05-25 |
2008-05-27 |
Agere Systems Inc. |
Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
|
US7653154B2
(en)
*
|
2004-05-25 |
2010-01-26 |
Agere Systems Inc. |
Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
|
US7487432B2
(en)
*
|
2004-05-25 |
2009-02-03 |
Agere Systems Inc. |
Method and apparatus for multiple step Viterbi detection with local feedback
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
GB0416508D0
(en)
*
|
2004-07-23 |
2004-08-25 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB0418830D0
(en)
|
2004-08-24 |
2004-09-22 |
Astrazeneca Ab |
Novel compounds
|
DE102004044827A1
(de)
|
2004-09-16 |
2006-03-23 |
Bayer Cropscience Ag |
Jod-phenylsubstituierte cyclische Ketoenole
|
WO2006056752A1
(en)
|
2004-11-23 |
2006-06-01 |
Astrazeneca Ab |
Phenoxyacetic acid derivatives useful for treating respiratory diseases
|
MX2007007830A
(es)
|
2004-12-23 |
2007-07-25 |
Glaxo Group Ltd |
Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandina.
|
AU2006216802B2
(en)
*
|
2005-02-22 |
2010-08-05 |
Merial Limited |
Methods for selectively treating COX-2 mediated disorders by administering gamma-tocopherol
|
EP2444419A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
CA2607913C
(en)
*
|
2005-05-05 |
2014-03-18 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
PE20080035A1
(es)
|
2005-09-07 |
2008-01-30 |
Amgen Fremont Inc |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
JP5155171B2
(ja)
|
2005-10-06 |
2013-02-27 |
アストラゼネカ・アクチエボラーグ |
新規化合物
|
TW200745003A
(en)
|
2005-10-06 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
JP2007275193A
(ja)
*
|
2006-04-04 |
2007-10-25 |
Fujifilm Corp |
光プローブおよび光断層画像化装置
|
AR061623A1
(es)
*
|
2006-06-26 |
2008-09-10 |
Novartis Ag |
Derivados de acido fenilacetico
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
CN101868443A
(zh)
|
2007-09-20 |
2010-10-20 |
特拉维夫大学拉莫特有限公司 |
N-苯基邻氨基苯甲酸衍生物及其用途
|
US20090082452A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched lumiracoxib
|
BRPI0907364A2
(pt)
|
2008-02-01 |
2015-07-14 |
Amira Pharmaceuticals Inc |
Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
|
US8242145B2
(en)
|
2008-02-14 |
2012-08-14 |
Panmira Pharmaceuticals, Llc |
Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
|
US8497381B2
(en)
|
2008-02-25 |
2013-07-30 |
Panmira Pharmaceuticals, Llc |
Antagonists of prostaglandin D2 receptors
|
WO2009145989A2
(en)
|
2008-04-02 |
2009-12-03 |
Amira Pharmaceuticals, Inc. |
Aminoalkylphenyl antagonists of prostaglandin d2 receptors
|
US20110190227A1
(en)
|
2008-07-03 |
2011-08-04 |
Amira Pharmaceuticals, Inc. |
Antagonists of Prostaglandin D2 Receptors
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
US8378107B2
(en)
|
2008-10-01 |
2013-02-19 |
Panmira Pharmaceuticals, Llc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
WO2010042652A2
(en)
|
2008-10-08 |
2010-04-15 |
Amira Pharmaceuticals, Inc. |
Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
|
EP2177215A1
(en)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-crystals of tramadol and NSAIDs
|
WO2010056741A2
(en)
*
|
2008-11-12 |
2010-05-20 |
Auspex Pharmaceuticals, Inc. |
Phenylacetic acid inhibitors of cyclooxygenase
|
WO2010057118A2
(en)
|
2008-11-17 |
2010-05-20 |
Amira Pharmaceuticals, Inc. |
Heterocyclic antagonists of prostaglandin d2 receptors
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
CN102596199A
(zh)
|
2009-07-31 |
2012-07-18 |
潘米拉制药公司 |
Dp2受体拮抗剂的眼用医药组合物
|
MX2012001542A
(es)
|
2009-08-05 |
2012-06-19 |
Panmira Pharmaceuticals Llc |
Antagonista dp2 y usos del mismo.
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
KR20120115989A
(ko)
*
|
2010-01-06 |
2012-10-19 |
판미라 파마슈티칼스, 엘엘씨 |
Dp2 길항제 및 이의 용도
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
WO2012004604A1
(en)
|
2010-07-09 |
2012-01-12 |
Convergence Pharmaceuticals Limited |
Tetrazole compounds as calcium channel blockers
|
US8892989B1
(en)
*
|
2010-08-26 |
2014-11-18 |
Clearslide, Inc. |
Method for searching companies and people
|
US8900798B2
(en)
|
2010-10-18 |
2014-12-02 |
Eastman Kodak Company |
On-press developable lithographic printing plate precursors
|
US20120090486A1
(en)
|
2010-10-18 |
2012-04-19 |
Celin Savariar-Hauck |
Lithographic printing plate precursors and methods of use
|
US20120141942A1
(en)
|
2010-12-03 |
2012-06-07 |
Domenico Balbinot |
Method of preparing lithographic printing plates
|
US20120141941A1
(en)
|
2010-12-03 |
2012-06-07 |
Mathias Jarek |
Developing lithographic printing plate precursors in simple manner
|
US20120141935A1
(en)
|
2010-12-03 |
2012-06-07 |
Bernd Strehmel |
Developer and its use to prepare lithographic printing plates
|
JP6058556B2
(ja)
|
2011-01-19 |
2017-01-11 |
クオンベルゲンセ プハルマセウトイカルス リミテッド |
CaV2.2カルシウムチャンネルブロッカーとしてのピペラジン誘導体
|
US20120199028A1
(en)
|
2011-02-08 |
2012-08-09 |
Mathias Jarek |
Preparing lithographic printing plates
|
KR20140097127A
(ko)
|
2011-09-16 |
2014-08-06 |
포비어 파마수티칼스 |
아닐린 유도체, 그의 제조법 및 그의 치료 용도
|
US8632941B2
(en)
|
2011-09-22 |
2014-01-21 |
Eastman Kodak Company |
Negative-working lithographic printing plate precursors with IR dyes
|
US9029063B2
(en)
|
2011-09-22 |
2015-05-12 |
Eastman Kodak Company |
Negative-working lithographic printing plate precursors
|
CN102311355B
(zh)
*
|
2011-09-26 |
2014-02-05 |
扬州天和药业有限公司 |
罗本考昔的一种制备方法
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
US8679726B2
(en)
|
2012-05-29 |
2014-03-25 |
Eastman Kodak Company |
Negative-working lithographic printing plate precursors
|
US9063423B2
(en)
|
2013-02-28 |
2015-06-23 |
Eastman Kodak Company |
Lithographic printing plate precursors and use
|
US9201302B2
(en)
|
2013-10-03 |
2015-12-01 |
Eastman Kodak Company |
Negative-working lithographic printing plate precursor
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
CN117427182A
(zh)
|
2017-03-14 |
2024-01-23 |
生化学工业株式会社 |
关节疾病处置用组合物及含有其的试剂盒
|
JP6489672B2
(ja)
|
2017-03-14 |
2019-03-27 |
生化学工業株式会社 |
関節疾患処置用組成物およびこれを含むキット
|
KR102069205B1
(ko)
|
2017-08-09 |
2020-01-22 |
연성정밀화학(주) |
라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
|
CN109694330B
(zh)
*
|
2017-10-24 |
2023-10-20 |
乳源瑶族自治县东阳光生物科技有限公司 |
一种酸的制备方法
|
EA202190330A1
(ru)
|
2018-07-27 |
2021-06-04 |
КРКА, д.д., НОВО МЕСТО |
Способ получения полиморфной формы робенакоксиба
|
CN109503399B
(zh)
*
|
2018-12-29 |
2021-12-24 |
江苏天和制药有限公司 |
一种罗本考昔的制备方法
|
CN110437090A
(zh)
*
|
2019-07-31 |
2019-11-12 |
江苏天和制药有限公司 |
一种罗本考昔三聚体及其制备方法
|
CN111807978B
(zh)
*
|
2020-07-29 |
2023-03-14 |
武汉川泰科技有限公司 |
一种罗贝考昔的制备方法
|
WO2022195579A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
|
EP4281183A1
(en)
|
2022-03-23 |
2023-11-29 |
Alivira Animal Health Limited |
An improved process for purification of robenacoxib
|